

**CLINICAL AND INSTRUMENTAL STUDY FOR THE
EVALUATION OF THE VOLUMIZING AND RE-SHAPING
EFFICACY OF A COSMETIC PRODUCT INTENDED FOR
MATURE SKIN**

TORSTONE SA
LE PRIVILÈGE LA CRÈME
135619129D 7 days Kühlzelle

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 | +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 | +39.0382.25504

Sede legale: Via Guido Rossa, 1 20024 Garbagnate M.se (MI) Italy, I P.I./C.F. 11093320155
Capitale Sociale € 161.834 i.v., C.C.I.A.A. MI 1437929 - Registro Società N. 342215
Centro di Saggio operante in BPL - Sistema di gestione qualità certificato ISO 9001
Iscritto al Registro Regione Lombardia ai fini dell'autocontrollo alimentare (N 030015309008)
Garbagnate M.se: Laboratorio di Prova Accreditato ACCREDIA LAB N 1318L (UNI CEI EN ISO/IEC 17025:2018)
L'elenco delle prove accreditate è consultabile su www.accredia.it



KEY PERSONNEL

Customer

TORSTONE SA
International Center Cointrin
Route de Pré-Bois, 20
Bât. C, 2è étage
CP1913
CH-1215 GENÈVE 15

Principal experimenter

Dr. **Gloria ROVEDA**
Degree in Medicine and Surgery, Specialist in Dermatology and Venereology
Consultant to Complife Italia s.r.l.

Study director

Dr. **Ileana DE PONTI**
Chemist and pharmaceutical technologist
Complife Italia s.r.l.

Data analysis & Report

Dr. **Federica RUGGERI**
Biologist
Complife Italia s.r.l.

Complife Italia S.r.l.

Complife Italia S.r.l.
Via Angelini, 21
27028 San Martino Siccomario (PV)
Italy
tel. +39-0382 25504 fax. +39-0382 536006
Mail: info@complifegroup.com

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504



INDEX

STUDY DESIGN	4
1.1. Title	4
1.2. Aim of the study	4
1.3. Tested Product	4
1.3.1. Information provided by the Customer	4
1.4. Ethical requirements	5
1.5. Subjects	5
1.5.1. Subjects selection	5
1.5.1.1. Inclusion criteria	5
1.5.1.2. Not inclusion criteria	5
1.5.1.3. Withdrawal of subjects	6
1.6. Study development	6
1.7. Materials and methods	6
1.7.1. Reshaping effect	6
1.7.2. Plumping effect	7
1.7.3. Wrinkle volume (skin profilometry)	7
1.7.4. Skin elasticity/firmness	7
1.7.5. Skin moisturization	8
1.7.6. Skin pH	8
1.7.7. Clinical evaluation	8
1.7.8. Self- assessment	9
1.7.9. Digital and Primos pictures	9
1.8. Results and statistics	9
1.8.1. Results	9
1.8.2. Statistical analysis	9
1.8.3. Interpretation of results	9
1.9. Start/end date of study	10
1.10. Report change record	10
PANEL DEMOGRAPHY	11
RESULTS	12
CONCLUSIONS	47
Annex 1 –Digital and Primos pictures	48



STUDY DESIGN

1.1. Title

Clinical and instrumental study for the evaluation of the volumizing and re-shaping efficacy of a cosmetic product intended for mature skin.

1.2. Aim of the study

The study is designed to evaluate the tolerability and the anti-aging activity of a cosmetic product for face and neck. Primary endpoints of the trial are the evaluation of the product volumizing, re-shaping and anti-sagging efficacy. Secondary endpoints are the evaluation of the product efficacy in filling wrinkles and moisturizing the skin.

In order to reach this goal a clinical/instrumental study is carried out on 25 female subjects aged over 50 years old, showing moderate/severe loss of skin tone, irregular face contour and visible nasolabial folds. Evaluations are performed at baseline (T0), 15 minutes after the first product application (T15min), after 28 (T28), 56 (T56) and 84 (T84) days of product use by means of non-invasive bioengineering techniques. Moreover, during the study volunteers fill in a self-assessment questionnaire.

1.3. Tested Product

1.3.1. Information provided by the Customer

- ☒ Product name: **LE PRIVILÈGE LA CRÈME 135619129D 7 days Kühlzelle**
- ☒ The tested cosmetic product conforms to REGULATION (EC) No 1223/2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 November 2009 on cosmetic products (recast) (Text with EEA relevance) and to their annexes.
- ☒ Way of use: apply morning and evening to clean, dry face and neck. Place a small amount of product in the palm and heat it in your hands. Gently massage the cream:
 - on face with fingertips, starting from the centre and proceeding outwards;
 - on the neck, from bottom to top.

Use small circular movements to facilitate absorption and stimulate the skin.

OVAL REMODELING RITUAL (to be performed in the evening, after application)

For greater effectiveness in reshaping and redefining the contour of the face oval, we suggest the following night massage ritual (repeat each gesture at least 5 times):

- start by stimulating lymphatic circulation: massage the sides of the neck with the fingertips with downward circular movements. Carry out on both sides of the neck.
 - to tighten the contours of the face, place the thumb under the chin and index finger on the mandible
 - run along the jaw towards the ears, pinching the contour of the oval and lifting the skin upwards at the same time. Make with both hands, first on one side and then on the other side of the face.
 - finish by smoothing the face with wide movements from the jaw to the forehead and from the centre outwards.
- ☒ Qualitative INCI formula: AQUA (WATER), CAPRYLIC/CAPRIC TRIGLYCERIDE, CETEARYL ALCOHOL, PROPANEDIOL, GLYCERIN, C10-18 TRIGLYCERIDES, COCO-CAPRYLATE/CAPRATE, BUTYLENE GLYCOL, GLYCERYL STEARATE CITRATE, MYRISTYL MYRISTATE, BUTYROSPERMUM PARKII (SHEA) BUTTER, APRICOT KERNEL OIL POLYGLYCERYL-4 ESTERS, 1,2-HEXANEDIOL, GLYCERYL STEARATE, SQUALANE, HYDROGENATED PHOSPHATIDYLCHOLINE, HYDROXYACETOPHENONE, MACADAMIA INTEGRIFOLIA SEED OIL, PARFUM (FRAGRANCE), PUNICA GRANATUM SEED OIL, RICINUS COMMUNIS (CASTOR) SEED OIL, SODIUM LAUROYL GLUTAMATE, PENTYLENE GLYCOL, SORBITAN LAURATE, SCLEROTIUM GUM, CHONDRUS CRISPUS POWDER, XANTHAN GUM, COMMIPHORA MUKUL RESIN EXTRACT, HELIANTHUS ANNUUS (SUNFLOWER) SEED OIL, TOCOPHEROL, TETRASODIUM GLUTAMATE DIACETATE, HYDROXYETHYLCELLULOSE, ACETYL DIPEPTIDE-1 CETYL ESTER, GLUCOSE, VETIVERIA ZIZANOIDES ROOT EXTRACT, CI 77492 Iron oxide, CERAMIDE NP, SODIUM HYDROXIDE.

Page 4 out 53

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504



1.4. Ethical requirements

The study is carried out following the ethical requirements listed below.

- I. All participants in the study must be healthy volunteers, aged over 18 years old.
- II. All participants in the study must be selected under the supervision of an experimenter, using inclusion/non-inclusion criteria.
- III. Volunteers must choose to participate of their own accord.
- IV. All participants in the study must be volunteers who are informed of the aim and the nature of the study.
- V. All participants in the study must be informed of the possible risks involved in the study.
- VI. All participants in the study must sign a written consent form before the study begins.
- VII. Before volunteers are exposed to the tested product, all safety information regarding the product and its individual ingredients must be assessed.
- VIII. All the study procedures are carried out in compliance with the ethical principles for medical research (Ethical Principles for Medical Research Involving Human Subjects, Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and its amendment)
- IX. All the precautions have to be taken to avoid that adverse reactions will appear.
- X. In case of non-expected/adverse skin reaction occurrence the medical investigating specialist will evaluate the severity of the reaction (reporting it in the data collecting sheet of the volunteer) and as a consequence will start the appropriate therapy.

1.5. Subjects

1.5.1. Subjects selection

The subjects participating in the study are selected under the supervision of a board-certified dermatologist from a panel of healthy subjects in accordance with the following inclusion and non-inclusion criteria.

1.5.1.1. Inclusion criteria

- ☒ Healthy female subjects
- ☒ Age over than 50 years old
- ☒ Caucasian ethnicity
- ☒ Subjects showing moderate/severe loss of skin tone
- ☒ Subjects showing irregular face contour
- ☒ Subjects showing visible nasolabial folds
- ☒ Willingness to not use products/submit to treatments likely to interfere with the product to be tested
- ☒ Subjects who did not expose to the sun/solar lamps, who use self-tanning products in the last month prior to the study
- ☒ Willingness to not vary the normal daily routine
- ☒ Commitment to be willing and able to comply with the study requirements
- ☒ Commitment to not use cosmetic products with the same activity of the study product during the study
- ☒ Subject informed about the study procedures and having signed an informed consent form

1.5.1.2. Not inclusion criteria

- ☒ Subjects who do not fit the inclusion criteria
- ☒ Sunburn, suntan, scars or active dermal lesions on the test area
- ☒ Subjects accustomed to use tanning beds
- ☒ Pregnant or breastfeeding women
- ☒ Subjects that have shown allergies to cosmetic products, toiletries, sunscreens and/or topical drugs
- ☒ Subjects having a skin condition that the Investigator deems inappropriate for participation
- ☒ Positive anamnesis for atopy (if this condition interferes with the test execution)



1.5.1.3. Withdrawal of subjects

A subject enrolled in the study can be withdrawn and considered as a drop-out when: (i) adverse reactions, judged severe and attributable to the tested product, occur, (ii) the subject is no longer eligible to participate in the study, (iii) the subject develops a pathological condition, not related to the study, but appearing during the study period, (iv) it is required the prescription of a concomitant treatment, (v) the study requirements are not satisfied (significant deviation from the protocol), (vi) significant non-compliance with respect to product use or to the study protocol.

1.6. Study development

The study is carried out as follow:

- **T0:** enrolment of 25 subjects according to inclusion/non-inclusion criteria. Clinical-instrumental assessment of the parameters under study before product use.
- **Product application** under the supervision of the experimenter.
- **T15min:** evaluation of skin pH 15 minutes after product application
- **T0-T84:** daily use of the product according to provided instructions.
- **T28:** instrumental assessment of the parameters under study (reshaping effect, plumping effect, filling effect, skin elasticity/firmness, skin moisturization) and clinical analysis (face ptosis, horizontal neck folds, neck sagging, skin tonicity) after 28 days of product use. Digital pictures acquisition. Volunteers are asked to express their opinion on tested product by answering to a questionnaire.
- **T56:** instrumental assessment of the parameters under study (reshaping effect, plumping effect, filling effect, skin elasticity/firmness, skin moisturization) and clinical analysis (face ptosis, horizontal neck folds, neck sagging, skin tonicity) after 56 days of product use. Digital pictures acquisition. Volunteers are asked to express their opinion on tested product by answering to a questionnaire.
- **T84:** instrumental assessment of the parameters under study (reshaping effect, plumping effect, filling effect, skin elasticity/firmness, skin moisturization) and clinical analysis (face ptosis, horizontal neck folds, neck sagging, skin tonicity) after 84 days of product use. Digital pictures acquisition. Volunteers are asked to express their opinion on tested product by answering to a questionnaire. At T84 the evaluations are performed on 20 out 25 subjects (the Customer decided to continue the study until 84 days after the study protocol approval and 5 subjects couldn't extend the study duration beyond 56 days).


1.7. Materials and methods

In the sections here below are reported the materials and methods employed in the study. All the study procedures are carried out under temperature and humidity-controlled conditions.

1.7.1. Reshaping effect

Lateral 3D images of the face are acquired by means of PrimosCR high-resolution large field (Canfield Imaging Systems, Fairfield, NJ). Product reshaping effect of face contour is assessed using a morphometric image analysis technique carried out in the jowl area. For further information see box 1.

BOX 1 - PrimosCR high-resolution large field 3D images.



The reshaping effect of the face contour is assessed by means of morphometric image analysis carried out on the photographic images acquired before and after product use. On each image, 3 measurements are made as reported in the figure here on the side. Subjects repositioning is ensured by a repositioning device (Canfield Scientific); while before/after images matching is ensured by an overlapping feature of the image analysis software.



1.7.2. Plumping effect

Lateral 3D images of the face are acquired by means of Primos^{CR} high-resolution large field (Canfield Imaging Systems, Fairfield, NJ). Product plumping effect on cheekbones is assessed by volume analysis with Primos^{CR}. For further information see box 2.

BOX 2 - Primos^{CR} high-resolution large field 3D images.




The cheekbones volume is measured on the 3D pictures taken by Primos^{CR} Large Field (Canfield Scientific). The measured parameter is the distance on the vertical plane between the before and after cheekbone prominence. The parameter is automatically calculated by the Primos^{CR} proprietary software (Vectra). Subjects repositioning is ensured by a repositioning device (Canfield Scientific); while before/after images matching is ensured by an overlapping feature of the image analysis software.


1.7.3. Wrinkle volume (skin profilometry)

Skin surface is quantitatively assessed by Primos 3D (GFMeasstechnik GmbH). Primos 3D is a non-contact in vivo skin measurement device based on structured light projection. In conjunction with a comprehensive 3-D measurement and evaluation software, the sensor allows to evaluate skin surface properties (i.e. wrinkle depth, volume, roughness etc.). In this study wrinkle volume of the nasolabial fold is evaluated. For further information see box 3.

BOX 3 - Skin profilometry by means of Primos 3D analysis



The technique. Primos 3D is a 3D scanner that create a point cloud (set of vertices in a three-dimensional coordinate system) of geometric samples on the surface of the subject. These points are then used to extrapolate the shape of the subject (a process called reconstruction). Like cameras, 3D-scanner have a cone-like field of view, and like cameras, they can only collect information about surfaces that are not obscured. While a camera collects color information about surfaces within its field of view, 3D scanners collect distance information about surfaces within its field of view. The "picture" produced by a 3D scanner describes the distance to a surface at each point in the picture (see the image in the insert).



Calculation of wrinkle volume. The software allows to select an area of which the volume of cavities is then calculated.

1.7.4. Skin elasticity/firmness


Skin elasticity measurement is based on the suction/elongation method and the subsequent release of the skin inside the opening of the instrument (Cutometer[®]MPA 580, Courage+Khazaka, electronic GmbH). During the suction/elongation phase the instrument generates, in fact, a constant negative pressure (450 mbar) able to aspirate the skin inside the measurement probe. The suction phase is followed by the release phase, in which the pressure inside the probe is switched to 0 mbar allowing the skin recovery after the elongation phase. An optical measurement system evaluates the depth of the skin inside the probe in the two phases of the measurement, the obtained data are then elaborated and showed graphically and numerically in order to calculate the viscoelastic properties of the skin. For further information see box 4.

- **R2 parameter** (gross elasticity or overall elasticity): it is the ratio between the residual deformation and the maximum elongation of the skin (U_a/U_f) and it indicates the ability of the skin to return to its original state of recovery after a stressing event. Closer the value is to 1, more elastic is the skin.



- **R0 parameter** (skin distensibility): it is the first max amplitude of the curve (Uf) and it represents the passive behaviour of the skin to a force (i.e. gravity). A reduction of R0 parameter indicates an improvement of the skin ability to oppose to the deformation imposed by the probe during the suction phase, than can be expressed as an improvement of skin firmness.

Box 4 (a) Skin elasticity measurement process. (b) R0 parameter. (c) R2 parameter.



1.7.5. Skin moisturization

Skin moisturization is evaluated by means of Corneometer® measurement. This measurement is based on the completely different dielectric constant of water (81) and other substances (mostly < 7). The measuring capacitor shows changes of capacitance according to the moisture content of the skin. A metallic lamina separates the metallic tracks (gold) in the probe head from the skin in order to prevent current conduction in the measured area. An electric field between the tracks with alternating attraction develops. One track builds up a surplus of electrons (minus charge) the other a lack of electrons (plus charge). The scatterfield penetrates the very first layer of the skin during the measurement and the capacitance is determined.

1.7.6. Skin pH

The used instrument is the SKIN pH-METER 905®, Courage + Khazaka GmbH. The measure is based on a combined electrode of high quality, in which both the glass electrode sensitive to H⁺ and the additional reference electrode are placed in the same site. It is connected to a handle probe containing the measurement electronics. Before the measurements, the SKIN pH-meter® 905 (Courage + Khazaka electronic GmbH) is calibrated using two buffer solutions with known pH (pH 4.01 and 1.7) as reference.

Measurement range: 0 to 12; accuracy: ± 0.1 pH.

1.7.7. Clinical evaluation

Clinical evaluations are carried out by the experimenter following clinical and photographic scales reported in the *Skin Aging Atlas Vol 1 - Caucasian Type - Bazin Roland* (half points are admitted):

- Ptosis of the lower part of the face (from 0 -no ptosis- to 5 -remarkable ptosis- scale)
- Horizontal neck folds (from 0 -no wrinkle- to 6 -remarkable wrinkle- scale)
- Neck sagging (from 0 -no sagging- to 6 or 7* -remarkable sagging- scale).

* Three types of scales are available: ("skinny", "intermediate" and "thick" necks) depending on the subject's morphology. The score is assigned according to the most appropriate scale for each subject.

Moreover, skin tonicity is evaluated according to an internal scale reported in box 5.

Box 5 Clinical classification of skin firmness	Score
NOT FIRM SKIN Unelastic skin and characterized by a strong loss of tone. The skin appears completely thinned like emptied, not dense and the tissues appear clearly relaxed. The skin has bad resistance to pinching and pulling, as well as a poor elastic recovery after traction.	1
NOT VERY FIRM SKIN Poorly elastic skin and characterized by an evident loss of tone. The skin appears thinned and less dense in some areas; the tissues start to relax. The skin has poor resistance to pinching and pulling, as well as a poor elastic recovery after traction.	2
SUFFICIENTLY FIRM SKIN Sufficiently elastic skin and characterized by a medium tone. The skin appears sufficiently full, plump and dense and the tissues appear slightly relaxed. The skin has sufficient resistance to	3

Page 8 out 53

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504

Sede legale: Via Guido Rossa, 1 20024 Garbagnate M.se (MI) Italy, I P.I./C.F. 11093320155
Capitale Sociale € 161.834 i.v., C.C.I.A.A. MI 1437929 - Registro Società N. 342215
Centro di Saggio operante in BPL - Sistema di gestione qualità certificato ISO 9001
Iscritto al Registro Regione Lombardia ai fini dell'autocontrollo alimentare (N 030015309008)
Garbagnate M.se: Laboratorio di Prova Accreditato ACCREDIA LAB N 1318L (UNI CEI EN ISO/IEC 17025:2018)
L'elenco delle prove accreditate è consultabile su www.accredia.it



pinching and pulling; the elastic recovery after traction is quite good.	
FIRM SKIN Elastic skin and characterized by a good tone. The skin appears full, plump and the tissues don't appear relaxed. The skin has good resistance to pinching and pulling; the elastic recovery after traction is good.	4
VERY FIRM SKIN Elastic skin and characterized by an excellent tone. The skin appears full, plump and the tissues don't appear relaxed. The skin has an excellent resistance to pinching and pulling; the elastic recovery after traction is excellent.	5

1.7.8. Self- assessment

At T28, T56 and at the end of the study (T84) volunteers are asked to express their opinion about product efficacy by answering to a questionnaire.

1.7.9. Digital and Primos pictures

Digital and Primos 3D (GFMeStechnik GmbH) pictures of face and neck are acquired by means of a digital reflex camera. Best pictures (2 cases for neck, 2 for nasolabial fold wrinkles, 2 for face ptosis) are provided to the Customer.

1.8. Results and statistics

1.8.1. Results

Results are reported in tables in their respective units.

1) Mean values are calculated as:

$$m = \frac{\sum_{i=1}^n p_i}{n}$$

where: p is the value of the parameter under analysis; n is the number of subjects participating in the study

2) Percentages are calculated as follows:

$$\%var. vs. T0 = \left(\frac{\sum_{i=1}^n p_i - p_0}{p_0} \right) \times 100$$

or

$$\% of subjects = \left(\frac{\sum_{i=1}^n answers}{n} \right) \times 100$$

where: p_i is the value of the parameter under analysis after product application; p₀ is the value of the parameter under analysis before product application; n is the number of subjects participating in the study

3) The mean standard error of data is calculated as:

$$SE = \frac{\sqrt{\frac{\sum_{i=1}^n (p_i^2) - \frac{(\sum_{i=1}^n p_i)^2}{n}}{(n-1)}}}{\sqrt{n}}$$

where: p is the value of the parameter under; n is the number of subjects participating in the study

All the calculations are done using a Microsoft® Office worksheet.

1.8.2. Statistical analysis

Instrumental data are submitted to two way test t of Student for paired data, while clinical data are submitted to Wilcoxon signed test. Variations are considered statistically significant when p value is < 0,05.

1.8.3. Interpretation of results

The study here above reported was designed to demonstrate the test product claim(s) in the current framework proposed by Commission Regulation (EU) No 655/2013. Endpoints are measured using techniques currently accepted in the cosmetic field while biases are minimized by procedure(s) standardization according to ISO 9001 Quality Management System. Data are analyzed and interpreted by skilled technician according to both

Page 9 out 53

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504

Sede legale: Via Guido Rossa, 1 20024 Garbagnate M.se (MI) Italy, I.P.I./C.F. 11093320155
Capitale Sociale € 161.834 i.v., C.C.I.A.A. MI 1437929 - Registro Società N. 342215
Centro di Saggio operante in BPL - Sistema di gestione qualità certificato ISO 9001
Iscritto al Registro Regione Lombardia ai fini dell'autocontrollo alimentare (N 030015309008)
Garbagnate M.se: Laboratorio di Prova Accreditato ACCREDIA LAB N 1318L (UNI CEI EN ISO/IEC 17025:2018)
L'elenco delle prove accreditate è consultabile su www.accredia.it



Customer	TORSTONE SA
Record no	H.E.HU.MP.NVO06.025.06.00_IT00003835/21
Date	rev 01 by 15/12/2021

descriptive and inferential statistical analysis procedures. Due to the lack of reference values in the cosmetic field, statistical significance (for instrumental analysis) and percentage of subjects showing an effect (for clinical/sensorial endpoints) are the primary criterion to evaluate the correspondence between the proposed claim(s) and the study output(s). In particular Intragroup (vs. T0) or intergroup (e.g. active vs. placebo, treated vs non treated) statistical analysis criterion to reject the null hypothesis (no product effect) is set at $p < 0.05$. For clinical evaluations, the positive effect of the product on the measured parameter is confirmed if more than 50% of the subjects register an improvement. Finally, for the self-assessment questionnaires, the performance and the pleasantness of the product must be perceived by at least 60% of the subjects. Whenever reference values or threshold values exists those values are used to validate product claim(s).

1.9. Start/end date of study

The table here below reports date of beginning and end of the study.

Start date	End date
20/08/2021	03/12/2021

1.10. Report change record

The table here below reports the change log of all approved changes made to the document that make up the course after initial approval.

Rev. no	Date	Description
00	09/12/2021	First release
01	15/12/2021	Modified end date in paragraph 1.9

- The results of the study reported in this document are only referred to the tested samples and the specific experimental conditions.
- Any part of this report can only be reproduced with the consent of Complife Italia s.r.l.
- A copy of this report is kept on file at Complife Italia s.r.l.
- Both the informed consent and the information forms are kept on file at Complife Italia s.r.l. for 10 years after the date of issue of the report

Page 10 out 53

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504

Sede legale: Via Guido Rossa, 1 20024 Garbagnate M.se (MI) Italy, I P.I./C.F. 11093320155
Capitale Sociale € 161.834 i.v., C.C.I.A.A. MI 1437929 - Registro Società N. 342215
Centro di Saggio operante in BPL - Sistema di gestione qualità certificato ISO 9001
Iscritto al Registro Regione Lombardia ai fini dell'autocontrollo alimentare (N 030015309008)
Garbagnate M.se: Laboratorio di Prova Accreditato ACCREDIA LAB N 1318L (UNI CEI EN ISO/IEC 17025:2018)
L'elenco delle prove accreditate è consultabile su www.accredia.it



PANEL DEMOGRAPHY

The following table reports the age of the enrolled subjects.

n.	Vol ID	AGE
01	M0208G	69
02	B0526A	66
03	F3656S	63
04	S3831A	66
05	B2947R	51
06	O1459P	66
07	A4087L	56
08	P4241M	55
09	B4523A	57
10	P4206M	64
11	P0322S	57
12	G4288O	57
13	P0285R	59
14	A0002C	53
15	T4004E	54
16	B5476M	50
17	L4007M	66
18	M1721L	65
19	T4522I	65
20	G4281E	56
21	G1999P	59
22	B0037L	65
23	M4290G	53
24	E3159L	58
25	G0656C	54
Mean		59
Min		50
Max		69

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504



RESULTS RESHAPING EFFECT

TABLE 1a The table reports the obtained data for each volunteer at T28. Reshaping effect is measured in three points (on check). Data are expressed in mm.

n	Vol ID	T0			T28			T28		
		1	2	3	1	2	3	1	2	3
01	M0208G	42,0695	45,7277	53,2080	41,3060	45,5615	52,9189	-0,764	-0,166	-0,289
02	B0526A	33,8123	42,6046	53,4140	33,7128	42,4040	53,4320	-0,099	-0,201	0,018
03	F3656S	34,1908	52,6217	54,2371	34,3770	52,6768	53,7434	0,186	0,055	-0,494
04	S3831A	30,1603	49,6631	55,2658	29,8860	48,9252	53,4821	-0,274	-0,738	-1,784
05	B2947R	41,4658	46,9403	56,1338	41,5306	47,1777	56,1635	0,065	0,237	0,030
06	O1459P	43,7331	55,6534	51,8916	44,3725	56,6484	52,4845	0,639	0,995	0,593
07	A4087L	20,7484	33,3294	56,8335	21,5224	32,8259	58,1197	0,774	-0,504	1,286
08	P4241M	41,9873	47,0929	54,6642	39,3054	44,9993	52,3779	-2,682	-2,094	-2,286
09	B4523A	32,8341	55,8081	58,1682	31,8843	55,1273	56,3964	-0,950	-0,681	-1,772
10	P4206M	35,7673	50,6439	57,7174	35,6598	48,7235	57,2697	-0,108	-1,920	-0,448
11	P0322S	33,2308	48,4996	55,0261	31,3440	48,2693	54,6075	-1,887	-0,230	-0,419
12	G4288O	41,4529	55,0414	53,9075	41,3496	55,8175	54,5170	-0,103	0,776	0,610
13	P0285R	30,4172	35,8349	45,2286	30,8971	36,4184	45,5580	0,480	0,584	0,329
14	A0002C	38,6372	45,9679	54,9984	36,4875	45,0552	53,9643	-2,150	-0,913	-1,034
15	T4004E	47,3443	51,3599	55,6486	48,4143	52,5512	57,7626	1,070	1,191	2,114
16	B5476M	41,1089	47,1553	53,9493	41,1165	47,0840	54,8293	0,008	-0,071	0,880
17	L4007M	37,0087	44,4024	49,0365	36,6476	43,5849	48,8613	-0,361	-0,818	-0,175
18	M1721L	49,8969	56,3296	55,7567	48,8872	53,5511	55,1595	-1,010	-2,779	-0,597
19	T4522I	34,4634	44,0151	56,7891	32,0954	43,3343	54,8479	-2,368	-0,681	-1,941
20	G4281E	33,5326	42,9091	52,8231	31,3847	41,3635	51,3893	-2,148	-1,546	-1,434
21	G1999P	40,3015	47,0609	55,0368	38,7347	45,2285	52,7919	-1,567	-1,832	-2,245
22	B0037L	32,8808	39,7253	49,5095	32,8663	38,7390	49,3425	-0,014	-0,986	-0,167
23	M4290G	34,4416	42,8592	54,4967	34,7000	44,2482	53,4160	0,258	1,389	-1,081
24	E3159L	48,3067	50,7109	54,7924	45,5522	48,1726	52,1832	-2,755	-2,538	-2,609
25	G0656C	36,0174	51,5524	53,1498	35,1636	49,9690	53,5676	-0,854	-1,583	0,418
Mean		37,432	47,340	54,067	36,768	46,738	53,567	-0,664	-0,602	-0,500
SEM		1,298	1,187	0,567	1,270	1,183	0,562	0,226	0,228	0,239
Test t vs T0		-	-	-	0,007	0,014	0,047	-1,7%	-1,3%	-0,9%
								var. vs T0		



TABLE 1b The table reports the obtained data for each volunteer at T56. Reshaping effect is measured in three points (on check). Data are expressed in mm.

n	Vol ID	T0			T56			Variation vs T0	T56		
		1	2	3	1	2	3		1	2	3
01	M0208G	42,4784	47,9333	54,2371	41,7517	46,2281	53,8634		-0,727	-1,705	-0,374
02	B0526A	37,7312	44,8340	53,4626	37,1583	44,1510	53,2105		-0,573	-0,683	-0,252
03	F3656S	34,9291	54,0907	55,9665	33,2590	53,4711	54,9880		-1,670	-0,620	-0,979
04	S3831A	31,8360	41,1810	50,2852	31,9808	43,0536	51,7686		0,145	1,873	1,483
05	B2947R	38,1474	45,1158	53,1275	36,1425	44,2525	52,3156		-2,005	-0,863	-0,812
06	O1459P	43,6148	56,2859	65,0727	42,1628	54,3906	62,9016		-1,452	-1,895	-2,171
07	A4087L	21,0050	37,9318	39,4093	21,4715	37,2920	38,2683		0,467	-0,640	-1,141
08	P4241M	37,4441	47,4577	59,8070	35,3872	45,8816	58,5899		-2,057	-1,576	-1,217
09	B4523A	34,2850	41,6250	51,4395	34,0280	42,2685	50,9031		-0,257	0,644	-0,536
10	P4206M	37,4234	51,1172	50,7839	36,0634	48,8317	50,1003		-1,360	-2,286	-0,684
11	P0322S	37,4235	40,8384	48,2140	36,3806	41,5018	47,8876		-1,043	0,663	-0,326
12	G4288O	45,0056	53,1775	58,6381	45,0322	53,6999	58,9000		0,027	0,522	0,262
13	P0285R	29,7663	40,7539	48,3308	28,1970	39,4841	47,0941		-1,569	-1,270	-1,237
14	A0002C	37,7776	45,4538	54,0412	37,4111	44,7879	52,9995		-0,367	-0,666	-1,042
15	T4004E	35,6186	44,9713	54,0831	36,5164	46,6088	54,1420		0,898	1,638	0,059
16	B5476M	39,8580	46,7935	55,1234	40,7314	46,9597	54,7643		0,873	0,166	-0,359
17	L4007M	41,1597	44,0971	47,3574	38,9748	42,1750	45,3068		-2,185	-1,922	-2,051
18	M1721L	50,5568	56,3346	59,9890	49,2208	55,0495	59,3493		-1,336	-1,285	-0,640
19	T4522I	35,5479	43,0878	55,4725	34,0000	41,7301	53,7834		-1,548	-1,358	-1,689
20	G4281E	31,7445	41,0003	51,5190	29,9369	39,1172	49,7137		-1,808	-1,883	-1,805
21	G1999P	32,5320	41,2284	48,5744	31,3301	39,8203	47,9482		-1,202	-1,408	-0,626
22	B0037L	27,4291	38,6044	49,1123	26,0656	36,8023	47,2896		-1,364	-1,802	-1,823
23	M4290G	34,6907	41,7625	51,1050	33,9557	41,1474	50,7300		-0,735	-0,615	-0,375
24	E3159L	48,2560	50,7695	54,5554	46,5812	48,6942	52,6691		-1,675	-2,075	-1,886
25	G0656C	35,4000	44,0957	49,1504	33,4964	42,5384	48,6013		-1,904	-1,557	-0,549
Mean		36,866	45,622	52,754	35,889	44,797	51,924	Mean	-0,977	-0,824	-0,831
SEM		1,274	1,067	1,023	1,255	1,045	1,025	SEM	0,183	0,230	0,165
Test t vs T0		-	-	-	0,000	0,001	0,000	Mean %	-2,6%	-1,8%	-1,6%
								var. vs T0			



TABLE 1c The table reports the obtained data for each volunteer at T84. Reshaping effect is measured in three points (on check). Data are expressed in mm.

n	Vol ID	T0			T84			Variation vs T0	T84		
		1	2	3	1	2	3		1	2	3
01	M0208G	42,1684	46,5480	54,1005	41,2841	45,1427	53,1000		-0,884	-1,405	-1,001
02	B0526A	36,0161	44,1476	56,5117	34,8199	42,8784	54,3155		-1,196	-1,269	-2,196
03	F3656S	-	-	-	-	-	-		-	-	-
04	S3831A	31,4942	40,5663	51,1507	32,5493	41,3345	51,9087		1,055	0,768	0,758
05	B2947R	-	-	-	-	-	-		-	-	-
06	O1459P	47,0301	51,4324	54,9244	44,2952	49,0610	53,4514		-2,735	-2,371	-1,473
07	A4087L	24,6413	33,0190	39,5174	23,8080	32,4143	38,5816		-0,833	-0,605	-0,936
08	P4241M	36,8504	48,0689	56,2847	34,5485	46,2469	54,3345		-2,302	-1,822	-1,950
09	B4523A	33,8321	40,5109	51,0169	33,7183	40,2324	50,0546		-0,114	-0,279	-0,962
10	P4206M	35,7274	43,6360	50,3580	34,1681	42,0382	49,6195		-1,559	-1,598	-0,738
11	P0322S	35,0979	42,1781	48,9376	34,0790	41,6062	48,5484		-1,019	-0,572	-0,389
12	G4288O	-	-	-	-	-	-		-	-	-
13	P0285R	30,9119	40,5864	47,6468	29,5164	39,4489	46,6887		-1,396	-1,138	-0,958
14	A0002C	37,2145	44,3260	53,4510	36,2457	43,5972	52,5980		-0,969	-0,729	-0,853
15	T4004E	37,6481	45,6947	53,6942	37,0610	44,9982	53,0258		-0,587	-0,697	-0,668
16	B5476M	41,0906	48,2050	55,1401	40,3208	47,6941	53,5186		-0,770	-0,511	-1,622
17	L4007M	37,3747	44,6352	50,3672	34,9896	42,5494	48,6317		-2,385	-2,086	-1,735
18	M1721L	46,4240	53,7997	59,4329	44,8864	52,6637	57,9525		-1,538	-1,136	-1,480
19	T4522I	36,6040	46,2385	56,5663	35,7443	45,5161	55,6357		-0,860	-0,722	-0,931
20	G4281E	33,9198	43,4052	52,0931	31,6721	42,0317	49,3853		-2,248	-1,374	-2,708
21	G1999P	34,1331	41,2598	47,6792	32,1529	39,6714	45,9542		-1,980	-1,588	-1,725
22	B0037L	35,2074	49,0802	61,6239	33,2668	47,3427	59,8032		-1,941	-1,738	-1,821
23	M4290G	35,9724	46,2721	55,0929	34,7458	45,2940	53,9381		-1,227	-0,978	-1,155
24	E3159L	-	-	-	-	-	-		-	-	-
25	G0656C	-	-	-	-	-	-		-	-	-
Mean		36,468	44,681	52,779	35,194	43,588	51,552	Mean	-1,274	-1,092	-1,227
SEM		1,131	1,013	1,079	1,082	0,953	1,041	SEM	0,196	0,160	0,166
Test t vs T0		-	-	-	0,000	0,000	0,000	Mean %	-3,5%	-2,4%	-2,3%
								var. vs T0			

Note The evaluation at T84 is performed on 20 out 25 enrolled subjects.

Comment Test product determined a reshaping effect of face contours (related to a statistically significant decrease of the length of the 3 segments) at each timepoint.



PLUMPING EFFECT


TABLE 2 The table reports the obtained data for each volunteer. Data output represent the variation vs. T0 recorded by the instrument and are expressed in mm. For this parameter, no intra-group statistical analysis can be performed.

n.	Vol ID	Variation vs T0	T28	T56	T84
01	M0208G		0,20	0,36	0,42
02	B0526A		0,19	0,27	0,34
03	F3656S		0,47	0,66	-
04	S3831A		0,28	0,33	0,65
05	B2947R		0,47	0,74	-
06	O1459P		0,08	0,30	0,41
07	A4087L		0,13	0,18	0,56
08	P4241M		0,08	0,15	0,61
09	B4523A		0,14	0,52	0,63
10	P4206M		0,11	0,23	0,18
11	P0322S		0,21	0,65	0,72
12	G4288O		0,05	0,55	-
13	P0285R		0,14	0,24	0,29
14	A0002C		0,23	0,38	0,37
15	T4004E		0,27	0,40	0,57
16	B5476M		0,04	0,38	0,48
17	L4007M		0,05	0,24	0,42
18	M1721L		0,25	0,48	0,57
19	T4522I		0,26	0,36	0,48
20	G4281E		0,21	0,60	0,71
21	G1999P		0,04	0,25	0,28
22	B0037L		0,23	0,29	0,58
23	M4290G		0,24	0,39	0,57
24	E3159L		0,14	0,42	-
25	G0656C		0,27	0,66	-
Mean			0,19	0,40	0,49
SEM			0,02	0,03	0,03
Max			0,47	0,74	0,72
Min			0,04	0,15	0,18

Note The evaluation at T84 is performed on 20 out 25 enrolled subjects.



GRAPH 2 The graph below reports the mean percentage variations obtained at each experimental time for the analysed skin parameter.



Comment Test product determined a plumping effect* on cheekbones by +0.19mm, by +0.40mm and by +0.49mm after 28, 56 and 84 days, respectively.

* An increase of the measured parameter indicates a plumping effect.



WRINKLE VOLUME IN THE NASOLABIAL FOLD

TABLE 3a The table reports the obtained data for each volunteer at T28. Data are expressed in mm³.

n	Vol ID	T0	T28	% VARIATION VS. T0
01	M0208G	12,14	11,25	-7,3%
02	B0526A	4,58	4,38	-4,4%
03	F3656S	6,25	6,70	7,2%
04	S3831A	6,13	6,07	-1,0%
05	B2947R	7,15	6,95	-2,8%
06	O1459P	14,41	12,14	-15,8%
07	A4087L	4,86	4,69	-3,5%
08	P4241M	2,71	2,70	-0,4%
09	B4523A	3,54	3,38	-4,5%
10	P4206M	3,54	3,38	-4,5%
11	P0322S	35,30	37,52	6,3%
12	G4288O	5,09	5,19	2,0%
13	P0285R	8,56	8,17	-4,6%
14	A0002C	39,33	35,10	-10,8%
15	T4004E	3,73	2,34	-37,3%
16	B5476M	3,51	3,56	1,4%
17	L4007M	26,03	23,51	-9,7%
18	M1721L	43,41	38,50	-11,3%
19	T4522I	6,87	6,70	-2,5%
20	G4281E	3,06	3,23	5,6%
21	G1999P	2,36	2,12	-10,2%
22	B0037L	8,21	8,44	2,8%
23	M4290G	2,62	2,71	3,4%
24	E3159L	2,96	2,75	-7,1%
25	G0656C	4,35	4,52	3,9%
Mean		10,43	9,84	-4,2%
SEM		2,41	2,24	
t-test vs. T0		--	0,060	
				Max -37,3%
				Min 7,2%



TABLE 3b The table reports the obtained data for each volunteer at T56. Data are expressed in mm³.

n	Vol ID	T0	T56	% VARIATION VS. T0
01	M0208G	12,77	12,02	-5,9%
02	B0526A	4,98	4,59	-7,8%
03	F3656S	6,05	5,96	-1,5%
04	S3831A	6,13	5,50	-10,3%
05	B2947R	7,16	5,45	-23,9%
06	O1459P	14,29	13,21	-7,6%
07	A4087L	4,27	3,97	-7,0%
08	P4241M	2,56	2,50	-2,3%
09	B4523A	4,01	3,67	-8,5%
10	P4206M	3,54	3,41	-3,7%
11	P0322S	34,56	34,11	-1,3%
12	G4288O	5,27	5,14	-2,5%
13	P0285R	8,52	6,61	-22,4%
14	A0002C	38,68	36,30	-6,2%
15	T4004E	3,50	3,12	-10,9%
16	B5476M	3,51	3,33	-5,1%
17	L4007M	27,60	26,27	-4,8%
18	M1721L	45,09	32,86	-27,1%
19	T4522I	6,89	6,68	-3,0%
20	G4281E	2,91	3,13	7,6%
21	G1999P	4,69	3,09	-34,1%
22	B0037L	7,93	7,54	-4,9%
23	M4290G	2,55	2,60	2,0%
24	E3159L	2,76	2,40	-13,0%
25	G0656C	3,13	3,19	1,9%
Mean		10,53	9,47	-8,1%
SEM		2,44	2,13	
t-test vs. T0		--	0,037	
				Max -34,1%
				Min 7,6%






TABLE 3c The table reports the obtained data for each volunteer at T84. Data are expressed in mm³.

n	Vol ID	T0	T84	% VARIATION VS. T0
01	M0208G	12,06	10,35	-14,2%
02	B0526A	4,66	4,28	-8,2%
03	F3656S	-	-	-
04	S3831A	7,06	6,10	-13,6%
05	B2947R	-	-	-
06	O1459P	14,52	14,15	-2,5%
07	A4087L	4,27	3,58	-16,2%
08	P4241M	2,57	2,49	-3,1%
09	B4523A	3,87	3,47	-10,3%
10	P4206M	2,50	2,41	-3,6%
11	P0322S	28,94	29,74	2,8%
12	G4288O	-	-	-
13	P0285R	23,98	20,09	-16,2%
14	A0002C	39,13	37,30	-4,7%
15	T4004E	3,80	3,01	-20,8%
16	B5476M	3,54	3,31	-6,5%
17	L4007M	4,97	4,28	-13,9%
18	M1721L	38,46	28,61	-25,6%
19	T4522I	6,81	6,16	-9,5%
20	G4281E	2,76	3,04	10,1%
21	G1999P	3,55	2,14	-39,7%
22	B0037L	8,03	6,33	-21,2%
23	M4290G	2,56	2,54	-0,8%
24	E3159L	-	-	-
25	G0656C	-	-	-
Mean		10,90	9,67	-10,9%
SEM		2,67	2,39	
t-test vs. T0		--	0,025	
				Max -39,7%
				Min 10,1%

Note The evaluation at T84 is performed on 20 out 25 enrolled subjects.



GRAPHS 2a,b,c The graphs below report the mean data obtained at each experimental time for the analysed skin parameter. The data are expressed as a mean $\pm$ SEM. Above the error bar the intragroup statistical analysis is reported as follows: *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$.



Comment Test product determined a statistically significant decrease of the wrinkle volume of the nasolabial fold by -8.1% at T56 and by -10.9% at T84.



SKIN ELASTICITY – R2 PARAMETER

TABLE 4a The table below shows the data obtained for each subject at T28 and T56. Data are expressed as Ua/Uf.

n	Vol ID	T0	T28	T56	% VARIATION vs. T0	T28	T56
01	M0208G	0,4468	0,5015	0,5638		12,2%	26,2%
02	B0526A	0,6264	0,6494	0,6481		3,7%	3,5%
03	F3656S	0,5831	0,6484	0,6937		11,2%	19,0%
04	S3831A	0,3897	0,4611	0,5026		18,3%	29,0%
05	B2947R	0,6776	0,6703	0,7087		-1,1%	4,6%
06	O1459P	0,4853	0,5225	0,5714		7,7%	17,7%
07	A4087L	0,6239	0,6902	0,7396		10,6%	18,5%
08	P4241M	0,6198	0,6166	0,6441		-0,5%	3,9%
09	B4523A	0,5537	0,6466	0,6908		16,8%	24,8%
10	P4206M	0,5487	0,5889	0,6304		7,3%	14,9%
11	P0322S	0,5736	0,6080	0,6372		6,0%	11,1%
12	G4288O	0,5949	0,6465	0,6907		8,7%	16,1%
13	P0285R	0,5570	0,5587	0,5997		0,3%	7,7%
14	A0002C	0,7170	0,7302	0,7566		1,8%	5,5%
15	T4004E	0,5728	0,5819	0,6460		1,6%	12,8%
16	B5476M	0,6763	0,7066	0,7440		4,5%	10,0%
17	L4007M	0,5687	0,5822	0,5130		2,4%	-9,8%
18	M1721L	0,5065	0,5370	0,5888		6,0%	16,2%
19	T4522I	0,5722	0,5427	0,5935		-5,2%	3,7%
20	G4281E	0,6380	0,6725	0,6925		5,4%	8,5%
21	G1999P	0,6471	0,6752	0,6697		4,3%	3,5%
22	B0037L	0,6119	0,6469	0,6978		5,7%	14,0%
23	M4290G	0,6371	0,6749	0,6983		5,9%	9,6%
24	E3159L	0,6642	0,6609	0,7193		-0,5%	8,3%
25	G0656C	0,6583	0,7199	0,7535		9,4%	14,5%
Mean		0,5900	0,6216	0,6558		5,7%	11,8%
SEM		0,0151	0,0142	0,0143		-5,2%	-9,8%
t-test vs. T0		--	0,000	0,000	Min	18,3%	29,0%
					Max		





TABLE 4b The table below shows the data obtained for each subject at T84. Data are expressed as Ua/Uf.

n	Vol ID	T0	T84	% VARIATION VS. T0	T84
01	M0208G	0,4468	0,6016		34,6%
02	B0526A	0,6264	0,6434		2,7%
03	F3656S	-	-		-
04	S3831A	0,3897	0,5277		35,4%
05	B2947R	-	-		-
06	O1459P	0,4853	0,6265		29,1%
07	A4087L	0,6239	0,7606		21,9%
08	P4241M	0,6198	0,6960		12,3%
09	B4523A	0,5537	0,7308		32,0%
10	P4206M	0,5487	0,6953		26,7%
11	P0322S	0,5736	0,6245		8,9%
12	G4288O	-	-		-
13	P0285R	0,5570	0,6491		16,5%
14	A0002C	0,7170	0,7988		11,4%
15	T4004E	0,5728	0,6658		16,2%
16	B5476M	0,6763	0,7625		12,7%
17	L4007M	0,5687	0,5501		-3,3%
18	M1721L	0,5065	0,6275		23,9%
19	T4522I	0,5722	0,6122		7,0%
20	G4281E	0,6380	0,7258		13,8%
21	G1999P	0,6471	0,7184		11,0%
22	B0037L	0,6119	0,7312		19,5%
23	M4290G	0,6371	0,7134		12,0%
24	E3159L	-	-		-
25	G0656C	-	-		-
Mean		0,5786	0,6731		17,2%
SEM		0,0175	0,0161	Min	-3,3%
t-test vs. T0		--	0,000	Max	35,4%

Note The evaluation at T84 is performed on 20 out 25 enrolled subjects.



GRAPHS 3a,b The graphs report the mean data obtained at each experimental time. Data are expressed as a mean $\pm$ SEM. Above the error bar the intra-group statistical analysis is reported as follows: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.



Comment Test product determined a statistically significant increase of R2 parameter by +5.7%, by +11.8% and by +17.2% at T28, T56 and T84, respectively. An increase of this parameter indicates an improvement of skin elasticity.



SKIN FIRMNESS – R0 PARAMETER

TABLE 5a The table below shows the data obtained for each subject at T28 and T56. Data are expressed as Uf.

n	Vol ID	T0	T28	T56	% VARIATION VS. T0	T28	T56
01	M0208G	0,5260	0,4650	0,4560		-11,6%	-13,3%
02	B0526A	0,3480	0,3200	0,3410		-8,0%	-2,0%
03	F3656S	0,4320	0,4070	0,3580		-5,8%	-17,1%
04	S3831A	0,4260	0,4140	0,4750		-2,8%	11,5%
05	B2947R	0,3660	0,3910	0,3610		6,8%	-1,4%
06	O1459P	0,3070	0,2840	0,2680		-7,5%	-12,7%
07	A4087L	0,3350	0,2970	0,2890		-11,3%	-13,7%
08	P4241M	0,2420	0,2530	0,2460		4,5%	1,7%
09	B4523A	0,4100	0,3650	0,3280		-11,0%	-20,0%
10	P4206M	0,3390	0,3140	0,3030		-7,4%	-10,6%
11	P0322S	0,3520	0,3520	0,2770		0,0%	-21,3%
12	G4288O	0,3110	0,2790	0,2550		-10,3%	-18,0%
13	P0285R	0,3770	0,3830	0,3550		1,6%	-5,8%
14	A0002C	0,4170	0,3840	0,3270		-7,9%	-21,6%
15	T4004E	0,4190	0,3970	0,3640		-5,3%	-13,1%
16	B5476M	0,3460	0,2960	0,2390		-14,5%	-30,9%
17	L4007M	0,3640	0,3590	0,3860		-1,4%	6,0%
18	M1721L	0,4700	0,4380	0,3540		-6,8%	-24,7%
19	T4522I	0,3740	0,3960	0,3640		5,9%	-2,7%
20	G4281E	0,3260	0,2870	0,2400		-12,0%	-26,4%
21	G1999P	0,3390	0,2970	0,3300		-12,4%	-2,7%
22	B0037L	0,3530	0,3240	0,3040		-8,2%	-13,9%
23	M4290G	0,3940	0,4120	0,4180		4,6%	6,1%
24	E3159L	0,2710	0,2690	0,2480		-0,7%	-8,5%
25	G0656C	0,3570	0,2840	0,2580		-20,4%	-27,7%
Mean		0,3680	0,3467	0,3258		-5,7%	-11,3%
SEM		0,0122	0,0119	0,0131			
t-test vs. T0		--	0,000	0,000			
					Max	-20,4%	-30,9%
					Min	6,8%	11,5%




TABLE 5b The table below shows the data obtained for each subject at T84. Data are expressed as Uf.

n	Vol ID	T0	T84	% VARIATION VS. T0
01	M0208G	0,5260	0,4260	-19,0%
02	B0526A	0,3480	0,3430	-1,4%
03	F3656S	-	-	-
04	S3831A	0,4260	0,4410	3,5%
05	B2947R	-	-	-
06	O1459P	0,3070	0,2470	-19,5%
07	A4087L	0,3350	0,2720	-18,8%
08	P4241M	0,2420	0,2300	-5,0%
09	B4523A	0,4100	0,3020	-26,3%
10	P4206M	0,3390	0,2860	-15,6%
11	P0322S	0,3520	0,2750	-21,9%
12	G4288O	-	-	-
13	P0285R	0,3770	0,3390	-10,1%
14	A0002C	0,4170	0,3080	-26,1%
15	T4004E	0,4190	0,3520	-16,0%
16	B5476M	0,3460	0,2330	-32,7%
17	L4007M	0,3640	0,3630	-0,3%
18	M1721L	0,4700	0,3220	-31,5%
19	T4522I	0,3740	0,3920	4,8%
20	G4281E	0,3260	0,2420	-25,8%
21	G1999P	0,3390	0,3190	-5,9%
22	B0037L	0,3530	0,3090	-12,5%
23	M4290G	0,3940	0,3710	-5,8%
24	E3159L	-	-	-
25	G0656C	-	-	-
Mean		0,3732	0,3186	-14,3%
SEM		0,0137	0,0136	
t-test vs. T0		--	0,000	
				Max -32,7%
				Min 4,8%

Note The evaluation at T84 is performed on 20 out 25 enrolled subjects.



GRAPHS 4a,b The graphs report the mean data obtained at each experimental time. Data are expressed as a mean $\pm$ SEM. Above the error bar the intra-group statistical analysis is reported as follows: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$.



Comment Test product determined a decrease of R0 parameter by -5.7%, by -11.3% and by -14.3% at T28, T56 and T84, respectively. A decrease of this parameter indicates an improvement of skin firmness and for marketing purposes obtained variation can be expressed in absolute value as an improvement of skin firmness.



SKIN MOISTURIZATION

TABLE 6a The table below reports the raw data obtained for each subject at T28 and T56. Data are expressed in corneometric units (c.u.).

n.	Vol ID	T0	T28	T56		T28	T56
01	M0208G	47,2	53,3	59,2	Variation % vs T0	12,9%	25,4%
02	B0526A	50,8	53,8	49,8		5,9%	-2,0%
03	F3656S	51,8	53,1	62,4		2,5%	20,5%
04	S3831A	54,2	57,0	61,5		5,2%	13,5%
05	B2947R	31,1	42,1	42,9		35,4%	37,9%
06	O1459P	33,6	39,8	46,1		18,5%	37,2%
07	A4087L	53,2	56,6	59,6		6,4%	12,0%
08	P4241M	44,6	50,9	58,7		14,1%	31,6%
09	B4523A	41,6	41,3	52,9		-0,7%	27,2%
10	P4206M	42,4	46,9	56,3		10,6%	32,8%
11	P0322S	40,5	44,9	54,3		10,9%	34,1%
12	G4288O	51,1	57,2	61,7		11,9%	20,7%
13	P0285R	45,7	46,9	54,9		2,6%	20,1%
14	A0002C	52,9	55,1	61,1		4,2%	15,5%
15	T4004E	32,5	42,2	49,0		29,8%	50,8%
16	B5476M	48,9	50,6	60,3		3,5%	23,3%
17	L4007M	33,3	40,3	39,6		21,0%	18,9%
18	M1721L	47,2	54,7	57,0		15,9%	20,8%
19	T4522I	50,6	45,4	54,7		-10,3%	8,1%
20	G4281E	30,0	41,3	45,9		37,7%	53,0%
21	G1999P	48,6	45,6	54,1		-6,2%	11,3%
22	B0037L	50,3	57,2	63,6		13,7%	26,4%
23	M4290G	44,6	46,8	55,9		4,9%	25,3%
24	E3159L	30,4	36,4	45,7		19,7%	50,3%
25	G0656C	43,1	51,2	62,5		18,8%	45,0%
Mean		44,0	48,4	54,8		11,6%	26,4%
SEM		1,6	1,3	1,3517	Max	37,7%	53,0%
TEST.t vs T0		--	0,000	0,000	Min	-10,3%	-2,0%





TABLE 6b The table below reports the raw data obtained for each subject at T84. Data are expressed in corneometric units (c.u.).

n.	Vol ID	T0	T84		T84
01	M0208G	47,2	59,2	Variation % vs T0	25,4%
02	B0526A	50,8	54,2		6,7%
03	F3656S	-	-		-
04	S3831A	54,2	63,5		17,2%
05	B2947R	-	-		-
06	O1459P	33,6	49,9		48,5%
07	A4087L	53,2	54,5		2,4%
08	P4241M	44,6	61,2		37,2%
09	B4523A	41,6	57,3		37,7%
10	P4206M	42,4	56,1		32,3%
11	P0322S	40,5	58,6		44,7%
12	G4288O	-	-		-
13	P0285R	45,7	60,1		31,5%
14	A0002C	52,9	62,1		17,4%
15	T4004E	32,5	48,0		47,7%
16	B5476M	48,9	63,2		29,2%
17	L4007M	33,3	44,7		34,2%
18	M1721L	47,2	56,3		19,3%
19	T4522I	50,6	54,6		7,9%
20	G4281E	30,0	53,2		77,3%
21	G1999P	48,6	63,6		30,9%
22	B0037L	50,3	68,7		36,6%
23	M4290G	44,6	62,1		39,2%
24	E3159L	-	-		-
25	G0656C	-	-		-
Mean		44,6	57,6		31,2%
SEM		1,6	1,3	Max	77,3%
TEST.t vs T0		--	0,000	Min	2,4%

Note The evaluation at T84 is performed on 20 out 25 enrolled subjects.



GRAPHS 5a,b The graphs set out the mean data obtained at each experimental time for the parameter under study. Data are expressed as a mean $\pm$ SEM. Above the error bar the intragroup statistical analysis is reported as follows: *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$.



Comment Test product determined a statistically significant increase of skin moisturization by +11.6%, by +26.4% and by +31.2% at T28, T56 and T84, respectively.




SKIN pH

TABLE 7 The table below reports the raw data obtained for each subject. Data are expressed as pH values.

n.	Vol ID	T0	T15min		T15min
01	M0208G	5,9	5,8	Variation % vs T0	-1,7%
02	B0526A	6,2	6,0		-3,2%
03	F3656S	5,1	5,1		0,0%
04	S3831A	6,4	6,0		-6,3%
05	B2947R	6,4	6,2		-3,1%
06	O1459P	6,5	6,4		-1,5%
07	A4087L	5,5	5,7		3,6%
08	P4241M	5,8	5,8		0,0%
09	B4523A	6,4	6,1		-4,7%
10	P4206M	5,9	5,7		-3,4%
11	P0322S	5,5	5,9		7,3%
12	G4288O	5,0	5,2		4,0%
13	P0285R	6,0	5,7		-5,0%
14	A0002C	5,2	5,5		5,8%
15	T4004E	6,3	6,0		-4,8%
16	B5476M	5,9	5,7		-3,4%
17	L4007M	5,7	5,5		-3,5%
18	M1721L	5,4	5,4		0,0%
19	T4522I	6,7	6,1		-9,0%
20	G4281E	6,3	6,4		1,6%
21	G1999P	5,5	5,3		-3,6%
22	B0037L	6,2	5,9		-4,8%
23	M4290G	5,3	5,1		-3,8%
24	E3159L	5,5	5,7		3,6%
25	G0656C	5,2	5,3		1,9%
Mean		5,8	5,7		-1,4%
SEM		0,1	0,1	Max	7,3%
TEST.t vs T0		--	0,065	Min	-9,0%



GRAPH 6 The graph sets out the mean data obtained at each experimental time for the parameter under study. Data are expressed as a mean $\pm$ SEM. Above the error bar the intragroup statistical analysis is reported as follows: *** $p < 0.001$; ** $p < 0.01$; * $p < 0.05$.



Comment Test product doesn't alter the basal skin pH 15 minutes after its first application.



CLINICAL ANALYSIS – FACE PTOSIS

TABLES 8a,b The tables report the clinical scores assigned by the dermatologist to each volunteer at T0, T28 and T56. Data are expressed according to scores reported in *Skin Aging Atlas Vol1 – Caucasian Type - Bazin Roland* (half points are admitted).

n.	Vol ID	T0	T28	T56
01	M0208G	2,0	2,0	2,0
02	B0526A	4,0	3,5	3,5
03	F3656S	2,0	1,5	1,5
04	S3831A	5,0	4,5	5,0
05	B2947R	4,0	3,5	3,5
06	O1459P	3,0	2,5	2,5
07	A4087L	2,0	2,0	1,5
08	P4241M	4,0	4,0	3,5
09	B4523A	2,0	2,0	1,5
10	P4206M	4,0	3,5	3,5
11	P0322S	2,0	2,0	2,0
12	G4288O	1,0	1,0	1,0
13	P0285R	2,0	2,0	2,0
14	A0002C	4,0	4,0	4,0
15	T4004E	2,0	2,0	2,0
16	B5476M	3,0	3,0	3,0
17	L4007M	5,0	5,0	5,0
18	M1721L	3,0	3,0	3,0
19	T4522I	5,0	5,0	4,5
20	G4281E	4,0	3,5	3,5
21	G1999P	2,0	2,0	2,0
22	B0037L	5,0	5,0	4,5
23	M4290G	2,0	1,5	1,5
24	E3159L	3,0	3,0	2,0
25	G0656C	2,0	2,0	2,0
Mean		3,1	2,9	2,8
SEM		0,2	0,2	0,2
Wilcoxon Rank sum test		--	0,003	0,000

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504




TABLE 8c The table reports the clinical scores assigned by the dermatologist to each volunteer at T0 and T84. Data are expressed according to scores reported in *Skin Aging Atlas Vol1 – Caucasian Type - Bazin Roland* (half points are admitted).

n.	Vol ID	T0	T84
01	M0208G	2,0	2,0
02	B0526A	4,0	3,5
03	F3656S	-	-
04	S3831A	5,0	5,0
05	B2947R	-	-
06	O1459P	3,0	2,0
07	A4087L	2,0	1,5
08	P4241M	4,0	3,5
09	B4523A	2,0	1,5
10	P4206M	4,0	3,0
11	P0322S	2,0	2,0
12	G4288O	-	-
13	P0285R	2,0	2,0
14	A0002C	4,0	4,0
15	T4004E	2,0	1,5
16	B5476M	3,0	2,5
17	L4007M	5,0	5,0
18	M1721L	3,0	3,0
19	T4522I	5,0	4,5
20	G4281E	4,0	3,5
21	G1999P	2,0	2,0
22	B0037L	5,0	5,0
23	M4290G	2,0	1,5
24	E3159L	-	-
25	G0656C	-	-
Mean		3,3	2,6
SEM		0,3	0,3
Wilcoxon Rank sum test		--	0,000

Note The evaluation at T84 is performed on 20 out 25 enrolled subjects.



GRAPH 7 The graph reports the percentage of subjects related to the effect.



Comment

A clinical improvement of face ptosis was observed in 32% of the enrolled subjects at T28, in 52% of them at T56, in 55% at T84.

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 | +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 | +39.0382.25504



CLINICAL ANALYSIS – HORIZONTAL NECK FOLDS

TABLES 9a,b The tables report the clinical scores assigned by the dermatologist to each volunteer at T0, T28 and T56. Data are expressed according to scores reported in *Skin Aging Atlas Vol1 – Caucasian Type - Bazin Roland* (half points are admitted).

n.	Vol ID	T0	T28	T56
01	M0208G	2,0	2,0	1,5
02	B0526A	3,0	3,0	2,5
03	F3656S	2,0	1,0	1,0
04	S3831A	2,0	2,0	2,0
05	B2947R	3,0	3,0	2,5
06	O1459P	2,0	1,5	1,5
07	A4087L	3,0	2,5	2,5
08	P4241M	2,0	2,0	1,5
09	B4523A	2,0	2,0	1,5
10	P4206M	4,0	3,5	3,5
11	P0322S	3,0	2,5	2,0
12	G4288O	2,0	2,0	2,0
13	P0285R	4,0	3,5	4,0
14	A0002C	3,0	3,0	3,0
15	T4004E	2,0	1,5	1,5
16	B5476M	2,0	1,5	1,5
17	L4007M	2,0	2,0	2,0
18	M1721L	3,0	2,5	2,5
19	T4522I	4,0	4,0	3,5
20	G4281E	4,0	3,5	3,5
21	G1999P	2,0	1,5	1,5
22	B0037L	5,0	4,5	4,0
23	M4290G	3,0	2,5	2,5
24	E3159L	2,0	1,5	1,0
25	G0656C	3,0	3,0	3,0
Mean		2,8	2,5	2,3
SEM		0,2	0,2	0,2
Wilcoxon Rank sum test		--	0,000	0,000




TABLE 9c the table reports the clinical scores assigned by the dermatologist to each volunteer at T0 and T84. Data are expressed according to scores reported in *Skin Aging Atlas Vol1 – Caucasian Type - Bazin Roland* (half points are admitted).

n.	Vol ID	T0	T84
01	M0208G	2,0	1,5
02	B0526A	3,0	2,0
03	F3656S	-	-
04	S3831A	2,0	2,0
05	B2947R	-	-
06	O1459P	2,0	1,0
07	A4087L	3,0	2,5
08	P4241M	2,0	2,0
09	B4523A	2,0	1,0
10	P4206M	4,0	3,5
11	P0322S	3,0	2,0
12	G4288O	-	-
13	P0285R	4,0	4,0
14	A0002C	3,0	2,5
15	T4004E	2,0	1,5
16	B5476M	2,0	2,0
17	L4007M	2,0	1,5
18	M1721L	3,0	2,0
19	T4522I	4,0	3,5
20	G4281E	4,0	3,0
21	G1999P	2,0	1,5
22	B0037L	5,0	4,5
23	M4290G	3,0	2,5
24	E3159L	-	-
25	G0656C	-	-
Mean		2,9	2,1
SEM		0,2	0,2
Wilcoxon Rank sum test		--	0,000

Note The evaluation at T84 is performed on 20 out 25 enrolled subjects.



GRAPH 8 The graph reports the percentage of subjects related to the effect.



Comment

A clinical improvement of horizontal neck folds was observed in 56% of the enrolled subjects at T28, in 76% of them at T56, in 80% at T84.

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504



CLINICAL ANALYSIS – NECK SAGGING

TABLES 10a,b The tables report the clinical scores assigned by the dermatologist to each volunteer at T0, T28 and T56. Data are expressed according to scores reported in *Skin Aging Atlas Vol1 – Caucasian Type - Bazin Roland* (half points are admitted).

n.	Vol ID	T0	T28	T56
01	M0208G	4,0	4,0	3,5
02	B0526A	3,0	3,0	3,0
03	F3656S	6,0	5,5	5,5
04	S3831A	3,0	3,0	3,0
05	B2947R	1,0	1,0	1,0
06	O1459P	4,0	4,0	4,0
07	A4087L	4,0	4,0	4,0
08	P4241M	2,0	2,0	2,0
09	B4523A	2,0	2,0	2,0
10	P4206M	4,0	4,0	4,0
11	P0322S	3,0	3,0	3,0
12	G4288O	3,0	2,5	2,5
13	P0285R	2,0	1,5	2,0
14	A0002C	4,0	4,0	4,0
15	T4004E	1,0	1,0	1,0
16	B5476M	3,0	3,0	3,0
17	L4007M	2,0	2,0	2,0
18	M1721L	4,0	4,0	4,0
19	T4522I	5,0	5,0	5,0
20	G4281E	4,0	4,0	4,0
21	G1999P	1,0	1,0	1,0
22	B0037L	5,0	5,0	4,5
23	M4290G	3,0	2,5	2,5
24	E3159L	3,0	3,0	2,5
25	G0656C	3,0	3,0	3,0
Mean		3,2	3,1	3,0
SEM		0,3	0,3	0,2
Wilcoxon Rank sum test		--	0,043	0,011

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504




TABLE 10c the table reports the clinical scores assigned by the dermatologist to each volunteer at T0 and T84. Data are expressed according to scores reported in *Skin Aging Atlas Vol1 – Caucasian Type - Bazin Roland* (half points are admitted).

n.	Vol ID	T0	T84
01	M0208G	4,0	3,0
02	B0526A	3,0	2,5
03	F3656S	-	-
04	S3831A	3,0	3,0
05	B2947R	-	-
06	O1459P	4,0	4,0
07	A4087L	4,0	4,0
08	P4241M	2,0	2,0
09	B4523A	2,0	2,0
10	P4206M	4,0	3,5
11	P0322S	3,0	3,0
12	G4288O	-	-
13	P0285R	2,0	2,0
14	A0002C	4,0	4,0
15	T4004E	1,0	1,0
16	B5476M	3,0	2,5
17	L4007M	2,0	2,0
18	M1721L	4,0	4,0
19	T4522I	5,0	5,0
20	G4281E	4,0	4,0
21	G1999P	1,0	1,0
22	B0037L	5,0	4,5
23	M4290G	3,0	2,5
24	E3159L	-	-
25	G0656C	-	-
Mean		3,2	2,8
SEM		0,3	0,3
Wilcoxon Rank sum test		--	0,015

Note The evaluation at T84 is performed on 20 out 25 enrolled subjects.



GRAPH 9 The graph reports the percentage of subjects related to the effect.



Comment

A clinical improvement of neck sagging was observed in 16% of the enrolled subjects at T28, in 24% of them at T56, in 30% at T84.



CLINICAL ANALYSIS – SKIN FIRMNESS

TABLES 11a,b The tables report the clinical scores assigned by the dermatologist at T0, T28 and T56. Data are expressed according to scores reported in box 5.

n.	Vol ID	T0	T28	T56
01	M0208G	1	2	2
02	B0526A	3	3	3
03	F3656S	2	3	3
04	S3831A	2	3	3
05	B2947R	3	3	4
06	O1459P	3	3	4
07	A4087L	3	3	3
08	P4241M	3	3	4
09	B4523A	3	3	4
10	P4206M	2	2	2
11	P0322S	2	3	4
12	G4288O	2	3	3
13	P0285R	2	3	3
14	A0002C	3	3	4
15	T4004E	2	3	3
16	B5476M	3	3	3
17	L4007M	2	2	2
18	M1721L	2	2	2
19	T4522I	2	2	3
20	G4281E	3	3	3
21	G1999P	3	3	4
22	B0037L	2	3	3
23	M4290G	2	3	3
24	E3159L	2	2	3
25	G0656C	3	3	3
Mean		2,4	2,8	3,1
SEM		0,1	0,1	0,1
Wilcoxon Rank sum test		--	0,003	0,000




TABLE 11c The table reports the clinical scores assigned by the dermatologist at T0 and T84. Data are expressed according to scores reported in box 5.

n.	Vol ID	T0	T84
01	M0208G	1	2
02	B0526A	3	3
03	F3656S	-	-
04	S3831A	2	3
05	B2947R	-	-
06	O1459P	3	4
07	A4087L	3	3
08	P4241M	3	4
09	B4523A	3	4
10	P4206M	2	3
11	P0322S	2	4
12	G4288O	-	-
13	P0285R	2	3
14	A0002C	3	4
15	T4004E	2	3
16	B5476M	3	4
17	L4007M	2	3
18	M1721L	2	3
19	T4522I	2	3
20	G4281E	3	4
21	G1999P	3	3
22	B0037L	2	3
23	M4290G	2	3
24	E3159L	-	-
25	G0656C	-	-
Mean		2,4	3,3
SEM		0,1	0,1
Wilcoxon Rank sum test		--	0,000



GRAPH 10 The graph reports the percentage of subjects related to the effect.



Comment

A clinical improvement of skin firmness was observed in 36% of the enrolled subjects at T28, in 68% of them at T56, in 85% at T84.

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504



SELF-ASSESSMENT

TABLE 12a,b,c,d The tables show the results obtained from the questionnaire filled in by each volunteer. Results are expressed as percentage (%) of subjects who expressed the same opinion among those proposed.

T15min

No.	Items	Very pleasant	Pleasant	Neither pleasant nor unpleasant	Unpleasant	Very unpleasant	Positive answers
01	What do you think about the product aspect?	28,0%	64,0%	8,0%	0,0%	0,0%	92,0%
02	What do you think about the product texture?	32,0%	64,0%	4,0%	0,0%	0,0%	96,0%
03	What do you think about the product fragrance?	28,0%	72,0%	0,0%	0,0%	0,0%	100,0%
04	What do you think about product spreadability?	28,0%	64,0%	8,0%	0,0%	0,0%	92,0%
No.	Items	Very good	Good	Not good	Bad		Positive answers
05	What do you think about product penetration?	20,0%	68,0%	12,0%	0,0%		88,0%
06	What is the after feel on the skin?	28,0%	56,0%	8,0%	8,0%		84,0%
07	What is your overall appreciation of this product?	24,0%	68,0%	8,0%	0,0%		92,0%
No.	Items	Yes, absolutely	Yes, mildly	Yes, slightly	Not		Positive answers
08	After the application, does the skin appear more nourished and hydrated?	40,0%	48,0%	8,0%	4,0%		96,0%
09	After application, does the skin appear softer?	44,0%	44,0%	8,0%	4,0%		96,0%
10	After application, have you noticed that skin dryness and tightening sensation are improved?	44,0%	44,0%	4,0%	8,0%		92,0%

Other comments: the product is not easily absorbed and my skin appears greasy (1 subject); very good product (1 subject).

T28

No.	Items	D'accordo	Moderately agreed	Not completely agreed	Not agreed	Positive answers
01	Your skin is more nourished and moisturized	80,0%	20,0%	0,0%	0,0%	100,0%
02	Your skin is smoother	64,0%	32,0%	4,0%	0,0%	96,0%
03	Skin elasticity and firmness appear improved	68,0%	32,0%	0,0%	0,0%	100,0%
04	Your skin looks plumper	52,0%	44,0%	4,0%	0,0%	96,0%
05	Face appear fuller	44,0%	48,0%	8,0%	0,0%	92,0%
06	Face contours appear reshaped and redefined	44,0%	36,0%	20,0%	0,0%	80,0%
07	Skin sagging appears reduced	44,0%	36,0%	20,0%	0,0%	80,0%
08	Fine lines and wrinkles are less visible	40,0%	40,0%	20,0%	0,0%	80,0%
No.	Items. After application, the following skin issues seem improved:	Strongly	Improved	Unchanged	Aggravated	Positive answers
09	Dehydration	28,0%	72,0%	0,0%	0,0%	100,0%
10	Lack of skin comfort and tightening sensation	24,0%	68,0%	8,0%	0,0%	92,0%
11	Sagging and irregular face	16,0%	56,0%	28,0%	0,0%	72,0%
12	Lack of skin firmness and elasticity	20,0%	76,0%	4,0%	0,0%	96,0%
13	Fines lines and wrinkles	16,0%	60,0%	24,0%	0,0%	76,0%
No.	Items. SUBSEQUENT USE OF THE PRODUCT	Luxe	Masstige	Mass market		
14	According to you, this product is sold in which market segment?	36,0%	56,0%	8,0%		-
No.	Items	Very good	Good	Not good	Bad	Positive answers
15	What is your overall appreciation of this product in terms of efficacy?	28,0%	72,0%	0,0%	0,0%	100,0%
No.	Items	Absolutely yes	Maybe	Probably not	Absolutely not	Positive answers
16	Would you continue using this product?	52,0%	48,0%	0,0%	0,0%	100,0%
17	Would you buy this product independently from price?	40,0%	56,0%	4,0%	0,0%	96,0%

Page 44 out 53

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 | +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 | +39.0382.25504

Sede legale: Via Guido Rossa, 1 20024 Garbagnate M.se (MI) Italy, I P.I./C.F. 11093320155
Capitale Sociale € 161.834 i.v., C.C.I.A.A. MI 1437929 - Registro Società N. 342215
Centro di Saggio operante in BPL - Sistema di gestione qualità certificato ISO 9001
Iscritto al Registro Regione Lombardia ai fini dell'autocontrollo alimentare (N 030015309008)
Garbagnate M.se: Laboratorio di Prova Accreditato ACCREDIA LAB N 1318L (UNI CEI EN ISO/IEC 17025:2018)
L'elenco delle prove accreditate è consultabile su www.accredia.it



T56

No.	Items	D'accordo	Moderately agreed	Not completely agreed	Not agreed	Positive answers
01	Your skin is more nourished and moisturized	80,0%	16,0%	4,0%	0,0%	96,0%
02	Your skin is smoother	72,0%	20,0%	8,0%	0,0%	92,0%
03	Skin elasticity and firmness appear improved	80,0%	16,0%	4,0%	0,0%	96,0%
04	Your skin looks plumper	60,0%	32,0%	8,0%	0,0%	92,0%
05	Face appear fuller	40,0%	52,0%	8,0%	0,0%	92,0%
06	Face contours appear reshaped and redefined	40,0%	44,0%	16,0%	0,0%	84,0%
07	Skin sagging appears reduced	40,0%	40,0%	20,0%	0,0%	80,0%
08	Fine lines and wrinkles are less visible	44,0%	44,0%	12,0%	0,0%	88,0%
No.	Items. After application, the following skin issues seem improved:	Strongly	Improved	Unchanged	Aggravated	Positive answers
09	Dehydration	48,0%	52,0%	0,0%	0,0%	100,0%
10	Lack of skin comfort and tightening sensation	44,0%	56,0%	0,0%	0,0%	100,0%
11	Sagging and irregular face	32,0%	40,0%	28,0%	0,0%	72,0%
12	Lack of skin firmness and elasticity	28,0%	64,0%	8,0%	0,0%	92,0%
13	Fines lines and wrinkles	24,0%	48,0%	28,0%	0,0%	72,0%
No.	Items. SUBSEQUENT USE OF THE PRODUCT	Luxe	Masstige	Mass market		
14	According to you, this product is sold in which market segment?	28,0%	64,0%	8,0%		-
No.	Items	Very good	Good	Not good	Bad	Positive answers
15	What is your overall appreciation of this product in terms of efficacy?	40,0%	60,0%	0,0%	0,0%	100,0%
No.	Items	Absolutely yes	Maybe	Probably not	Absolutely not	Positive answers
16	Would you continue using this product?	56,0%	40,0%	4,0%	0,0%	96,0%
17	Would you buy this product independently from price?	48,0%	48,0%	0,0%	4,0%	96,0%

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legallmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504



T84

No.	Items	D'accordo	Moderately agreed	Not completely agreed	Not agreed	Positive answers
01	Your skin is more nourished and moisturized	80,0%	15,0%	5,0%	0,0%	95,0%
02	Your skin is smoother	70,0%	25,0%	5,0%	0,0%	95,0%
03	Skin elasticity and firmness appear improved	65,0%	30,0%	5,0%	0,0%	95,0%
04	Your skin looks plumper	60,0%	35,0%	5,0%	0,0%	95,0%
05	Face appear fuller	45,0%	45,0%	10,0%	0,0%	90,0%
06	Face contours appear reshaped and redefined	45,0%	45,0%	10,0%	0,0%	90,0%
07	Skin sagging appears reduced	40,0%	40,0%	20,0%	0,0%	80,0%
08	Fine lines and wrinkles are less visible	45,0%	45,0%	10,0%	0,0%	90,0%
No.	Items. After application, the following skin issues seem improved:	Strongly	Improved	Unchanged	Aggravated	Positive answers
09	Dehydration	50,0%	45,0%	5,0%	0,0%	95,0%
10	Lack of skin comfort and tightening sensation	60,0%	35,0%	5,0%	0,0%	95,0%
11	Sagging and irregular face	40,0%	30,0%	30,0%	0,0%	70,0%
12	Lack of skin firmness and elasticity	40,0%	55,0%	5,0%	0,0%	95,0%
13	Fines lines and wrinkles	35,0%	55,0%	5,0%	5,0%	90,0%
No.	Items. SUBSEQUENT USE OF THE PRODUCT	Luxe	Masstige	Mass market		
14	According to you, this product is sold in which market segment?	30,0%	70,0%	0,0%		-
No.	Items	Very good	Good	Not good	Bad	Positive answers
15	What is your overall appreciation of this product in terms of efficacy?	35,0%	60,0%	5,0%	0,0%	95,0%
No.	Items	Absolutely yes	Maybe	Probably not	Absolutely not	Positive answers
16	Would you continue using this product?	70,0%	25,0%	5,0%	0,0%	95,0%
17	Would you buy this product independently from price?	55,0%	35,0%	10,0%	0,0%	90,0%

Note Data collected at T84 refer to 20 out 25 subjects.

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 I +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 I +39.0382.25504



CONCLUSIONS

According to the obtained results we can conclude that the tested product:

TORSTONE SA **LE PRIVILÈGE LA CRÈME** **135619129D 7 days Kühlzelle**

after 84* day-use, determined:

- a reshaping effect of face contours (related to a statistically significant decrease of the length of the 3 segments) at T28, T56 and T84;
- a plumping effect** on cheekbones by +0.19mm, by +0.40mm and by +0.49mm after 28, 56 and 84 days, respectively;
- a decrease of the wrinkle volume of the nasolabial fold by -8.1% at T56 and by -10.9% at T84;
- an increase of R2 parameter (related to an improvement of skin elasticity) by +5.7%, by +11.8% and by +17.2% at T28, T56 and T84, respectively;
- a decrease of R0 parameter (related to an increase of skin firmness) by -5.7%, by -11.3% and by -14.3% at T28, T56 and T84, respectively;
- an increase of skin moisturization by +11.6%, by +26.4% and by +31.2% at T28, T56 and T84, respectively.

Moreover, the pH mean value remains almost unvaried 15 minutes after the first product use, index that it doesn't alter the basal skin conditions.

All the reported variations are statistically significant vs T0.

* Data collected at T28 and T56 refer to 25 subjects; data collected at T84 refer to 20 subjects.

** An increase of the measured parameter indicates a plumping effect.

The clinical analysis showed:

- an improvement of face ptosis in 52% of the enrolled subjects at T56 and in 55% of them at T84;
- an improvement of horizontal neck folds in 56% of the enrolled subjects at T28, in 76% of them at T56, in 80% at T84;
- an improvement of skin tonicity in 68% of the enrolled subjects at T56 and in 85% of them at T84.

Finally, the product was positively judged for all the investigated aspects by most of the enrolled subjects.

Principal experimenter

Dr. Gloria Roveda

Data analysis and report

Dr. Federica Ruggeri

Study Director

Dr. Ileana De Ponti

Page 47 out 53

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 | +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 | +39.0382.25504

Sede legale: Via Guido Rossa, 1 20024 Garbagnate M.se (MI) Italy, I.P.I./C.F. 11093320155
Capitale Sociale € 161.834 i.v., C.C.I.A.A. MI 1437929 - Registro Società N. 342215
Centro di Saggio operante in BPL - Sistema di gestione qualità certificato ISO 9001
Iscritto al Registro Regione Lombardia ai fini dell'autocontrollo alimentare (N 030015309008)
Garbagnate M.se: Laboratorio di Prova Accreditato ACCREDIA LAB N 1318L (UNI CEI EN ISO/IEC 17025:2018)
L'elenco delle prove accreditate è consultabile su www.accredia.it



Annex 1 –Digital pictures

Vol 11 - Horizontal neck folds



COMPLIFE Italia S.r.l.


info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 | +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 | +39.0382.25504

Sede legale: Via Guido Rossa, 1 20024 Garbagnate M.se (MI) Italy, I.P.I./C.F. 11093320155
Capitale Sociale € 161.834 i.v., C.C.I.A.A. MI 1437929 - Registro Società N. 342215
Centro di Saggio operante in BPL - Sistema di gestione qualità certificato ISO 9001
Iscritto al Registro Regione Lombardia ai fini dell'autocontrollo alimentare (N 030015309008)
Garbagnate M.se: Laboratorio di Prova Accreditato ACCREDIA LAB N 1318L (UNI CEI EN ISO/IEC 17025:2018)
L'elenco delle prove accreditate è consultabile su www.accredia.it



Vol 18 - Horizontal neck folds



COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 | +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 | +39.0382.25504

Sede legale: Via Guido Rossa, 1 20024 Garbagnate M.se (MI) Italy, I P.I./C.F. 11093320155
Capitale Sociale € 161.834 i.v., C.C.I.A.A. MI 1437929 - Registro Società N. 342215
Centro di Saggio operante in BPL - Sistema di gestione qualità certificato ISO 9001
Iscritto al Registro Regione Lombardia ai fini dell'autocontrollo alimentare (N 030015309008)
Garbagnate M.se: Laboratorio di Prova Accreditato ACCREDIA LAB N 1318L (UNI CEI EN ISO/IEC 17025:2018)
L'elenco delle prove accreditate è consultabile su www.accredia.it




Vol 6 - Face ptosis

T0



T28



T56



T84



COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 | +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 | +39.0382.25504



Vol 10 - Face ptosis



Page 51 out 53

COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com


Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 | +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 | +39.0382.25504

Sede legale: Via Guido Rossa, 1 20024 Garbagnate M.se (MI) Italy, I P.I./C.F. 11093320155
Capitale Sociale € 161.834 i.v., C.C.I.A.A. MI 1437929 - Registro Società N. 342215
Centro di Saggio operante in BPL - Sistema di gestione qualità certificato ISO 9001
Iscritto al Registro Regione Lombardia ai fini dell'autocontrollo alimentare (N 030015309008)
Garbagnate M.se: Laboratorio di Prova Accreditato ACCREDIA LAB N 1318L (UNI CEI EN ISO/IEC 17025:2018)
L'elenco delle prove accreditate è consultabile su www.accredia.it




Vol 13 – Wrinkle volume of the nasolabial fold


T0




T28



T56



T84



COMPLIFE Italia S.r.l.

info@complifegroup.com
complifeitalia@legalmail.it
complifegroup.com

Sedi principali:
GARBAGNATE MILANESE (MI), Via Guido Rossa 1, 20024 | +39.02.990.25138
SAN MARTINO SICCOMARIO (PV), Via Monsignor Angelini 21, 27028 | +39.0382.25504



Vol 21 – Wrinkle volume of the nasolabial fold

